Pfizer Inc. has released its 2025 Form 10-K report, detailing a 2% decrease in total revenues to $62.6 billion, primarily due to operational declines, with reported diluted EPS at $1.36 and adjusted diluted EPS up by 4% to $3.22. The report highlights strategic initiatives focused on R&D, market leadership, and cost realignment, while addressing significant challenges including pricing pressures, competition, patent expirations, and geopolitical risks. Pfizer aims to maximize key transactions, achieve R&D milestones, and invest in post-2028 growth, along with committing to net-zero emissions by 2040.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
PFIZER INC SEC 10-K Report
Pfizer Inc. has released its 2025 Form 10-K report, detailing a 2% decrease in total revenues to $62.6 billion, primarily due to operational declines, with reported diluted EPS at $1.36 and adjusted diluted EPS up by 4% to $3.22. The report highlights strategic initiatives focused on R&D, market leadership, and cost realignment, while addressing significant challenges including pricing pressures, competition, patent expirations, and geopolitical risks. Pfizer aims to maximize key transactions, achieve R&D milestones, and invest in post-2028 growth, along with committing to net-zero emissions by 2040.